everolimus (RAD001)

Phase 1/2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Tuberous Sclerosis

Conditions

Tuberous Sclerosis, Angiolipoma

Trial Timeline

Dec 1, 2008 → Sep 1, 2013

NCT ID

NCT00792766

About everolimus (RAD001)

everolimus (RAD001) is a phase 1/2 stage product being developed by Novartis for Tuberous Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00792766. Target conditions include Tuberous Sclerosis, Angiolipoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01514448	Approved	Completed	May 21, 2012	Apr 1, 2016	Metastatic Renal Cell Carcinoma (mRCC)
NCT01365468	Phase 2	Terminated	Apr 1, 2012	Apr 1, 2015	Plexiform Neurofibroma Associated With Neurofibromatosis Type 1
NCT01595009	Approved	Completed	Apr 27, 2011	Aug 9, 2016	Neuroendocrine Tumors
NCT01152801	Phase 1	Completed	May 1, 2010	Dec 1, 2013	Metastatic Renal Cell Carcinoma
NCT01022996	Phase 2	Completed	Dec 1, 2009	Nov 1, 2014	Hodgkin Lymphoma
NCT00792766	Phase 1/2	Completed	Dec 1, 2008	Sep 1, 2013	Tuberous Sclerosis
NCT00426530	Phase 1	Completed	Feb 1, 2007	Jun 1, 2010	Breast Neoplasms
NCT00419159	Phase 2	Completed	Dec 1, 2006	Mar 1, 2009	Colorectal Cancer
NCT00154297	Approved	Completed	Jun 1, 2005	—	Renal Transplantation
NCT00170794	Phase 3	Completed	Sep 1, 2004	—	Cardiac Transplantation
NCT00531440	Phase 3	Completed	Nov 1, 2001	—	Renal Transplantation
NCT00531063	Phase 3	Completed	Nov 1, 2001	—	Renal Transplantation

Competing Products

13 competing products in Tuberous Sclerosis

See all competitors

Product	Company	Stage	Hype Score
Everolimus (RAD001) + Everolimus Placebo	Novartis	Phase 3	77
Everolimus + Placebo	Novartis	Phase 3	77
RAD001	Novartis	Phase 1/2	41
Placebo + Everolimus (RAD001)	Novartis	Phase 2	52
RAD001 + Placebo	Novartis	Phase 2	52
RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)	Novartis	Phase 3	77
Everolimus	Novartis	Phase 1/2	41
everolimus	Novartis	Phase 3	77
sirolimus	Pfizer	Phase 2	51
GWP42003-P	Jazz Pharmaceuticals	Phase 3	74
GWP42003-P	Jazz Pharmaceuticals	Phase 3	74
GWP42003-P + Placebo	Jazz Pharmaceuticals	Phase 3	74
Cannabidiol Oral Solution [Epidiolex]	Jazz Pharmaceuticals	Approved	82

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved